Last reviewed · How we verify
NCT06554587
Investigation of Three Biomarkers for the Detection of Prostate Cancer
trial testing Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA) in Cancer of Prostate in 137 participants. Currently enrolling.
7 January 2026
Quick facts
| Lead sponsor | Medtechtomarket Consulting Ltd |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 7 January 2025 |
| Primary completion | 7 January 2026 |
| Estimated completion | 7 March 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Conditions studied
- Cancer of Prostate — all drugs for Cancer of Prostate →
Sponsor
Medtechtomarket Consulting Ltd
Who can join
18 and older, male only, with Cancer of Prostate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test. This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06554587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Prostate
Currently open trials in the same condition.
- NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
- NCT04887935 — Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer · Phase 1 · recruiting
- NCT05653063 — ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer · recruiting
- NCT06318559 — Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention · NA · recruiting
- NCT05214937 — A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06554587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medtechtomarket Consulting Ltd
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06554587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing